Physician profile
Amy Dunetz
NPI 1780606889
$14,481.28
in general payments reported to CMS, 2019-2025
18 companies · $79.19 in 2025
The $79.19 reported for 2025 was less than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $24.96 · 2021: $1,827 · 2022: $501 · 2023: $308 · 2024: $11K · 2025: $79.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $11K · Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $11,200.00 |
| Food and Beverage | $634.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $11,200.00 | 2024 | |
| Biotissue Holdings INC. | $1,756.69 | 2021 | |
| Aroa Biosurgery Incorporated | $567.19 | 2022-2024 | |
| Triad Life Sciences INC. | $189.28 | 2022 | |
| Merck Sharp & Dohme LLC | $177.57 | 2019 | |
| Smith+Nephew, INC. | $164.23 | 2019-2022 | |
| Mimedx Group, INC. | $79.19 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $65.86 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $44.66 | 2022-2023 | Krystexxa |
| Zyla Life Sciences, INC. | $43.36 | 2019 | |
| Organogenesis INC. | $42.32 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $41.55 | 2021 | |
| Amgen INC. | $32.04 | 2024 | Krystexxa |
| Kci USA, INC. | $22.73 | 2022 | |
| Heron Therapeutics, INC. | $16.27 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $13.05 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Zimmer Biomet Holdings, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Dunetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.